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To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti–
interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein–IgG–associated dis-
ease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD).
Methods
Annualized relapse rate (ARR), Expanded Disability Status Scale score, MRI, autoantibody
titers, pain, and adverse events were retrospectively evaluated in 57 patients withMOGAD (n =
14), aquaporin-4 (AQP4)-IgG seropositive (n = 36), and seronegative NMOSD (n = 7; 12%),
switched to TCZ from previous immunotherapies, particularly rituximab.
Results
Patients received TCZ for 23.8 months (median; interquartile range 13.0–51.1 months), with
an IV dose of 8.0 mg/kg (median; range 6–12 mg/kg) every 31.6 days (mean; range 26–44
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days). For MOGAD, the median ARR decreased from 1.75 (range 0.5–5) to 0 (range 0–0.9; p = 0.0011) under TCZ. A similar
effect was seen for AQP4-IgG+ (ARR reduction from 1.5 [range 0–5] to 0 [range 0–4.2]; p < 0.001) and for seronegative
NMOSD (from 3.0 [range 1.0–3.0] to 0.2 [range 0–2.0]; p = 0.031). During TCZ, 60% of all patients were relapse free (79% for
MOGAD, 56% for AQP4-IgG+, and 43% for seronegative NMOSD). Disability follow-up indicated stabilization. MRI in-
flammatory activity decreased inMOGAD (p = 0.04; for the brain) and in AQP4-IgG+NMOSD (p < 0.001; for the spinal cord).
Chronic pain was unchanged. Regarding only patients treated with TCZ for at least 12 months (n = 44), ARR reductions were
confirmed, including the subgroups of MOGAD (n = 11) and AQP4-IgG+ patients (n = 28). Similarly, in the group of patients
treated with TCZ for at least 12 months, 59% of them were relapse free, with 73% for MOGAD, 57% for AQP4-IgG+, and 40%
for patients with seronegative NMOSD. No severe or unexpected safety signals were observed. Add-on therapy showed no
advantage compared with TCZ monotherapy.
Discussion
This study provides Class III evidence that long-term TCZ therapy is safe and reduces relapse probability in MOGAD and
AQP4-IgG+ NMOSD.
Myelin oligodendrocyte glycoprotein (MOG)-IgG–associated
disease (MOGAD) and neuromyelitis optica spectrum disor-
der (NMOSD)with or without anti–aquaporin-4 (AQP4)-IgG
are antibody-mediated, chronic inflammatory CNS conditions
in most cases.1-4 Although the clinical presentation with uni-
lateral or bilateral optic neuritis (ON), longitudinally extensive
transverse myelitis, or brain stem syndromes may be similar in
MOGAD and NMOSD, demographic, clinical, imaging, and
pathophysiologic findings strongly suggest the presence of 2
distinct disease entities.4-8 As MOGAD, excluding acute dis-
seminated encephalomyelitis (ADEM), and NMOSD typically
follow a relapsing course in adults,3,9 attack prevention is key to
avoid disability accumulation. Recently, a variety of therapeutic
strategies such as CD19/20-mediated B-cell depletion,10,11
complement inhibition,12 and interleukin-6 (IL-6) receptor
blockade13,14 were successfully investigated in pivotal NMOSD
trials, particularly in AQP4-IgG+ patients. Yet, insights con-
cerning the effectiveness and safety of such agents in MOGAD
are scarce.
IL-6 plays an important role in the pathophysiology of
NMOSD.15 Increased levels were detected in the serum and
CSF, particularly during attacks.16 IL-6 promotes the dif-
ferentiation of inflammatory Th17 cells17 and the pro-
duction of AQP4-IgG by B cell–derived plasmablasts in
NMOSD18 and increases the permeability of the blood-brain
barrier,19 facilitating CNS inflammation. The efficacy of IL-6
receptor blockade in AQP4-IgG+ NMOSD was suggested
by studies using tocilizumab (TCZ) in adults and children20-
26 and demonstrated by 2 pivotal trials of satralizumab,
whereas the effect in AQP4-IgG–seronegative patients was
less evident.13,14 As AQP4-IgG+ NMOSD and MOGAD
both display antibody- and complement-mediated CNS in-
jury and similar inflammatory CSF profiles (with elevated
IL-6),27,28 IL6-blockade may also be beneficial in MOGAD,
supported by recent case reports.23,25,26,29-33 This retro-
spective multicenter study explored the safety and efficacy of
TCZ in patients with MOGAD and is able to connect these
findings with the effects of TCZ in classical (i.e., AQP4-
IgG+) or double-seronegative NMOSD.
Patients and Previous Treatments
Fifty-seven patients with relapsing MOGAD (n = 14),34 ex-
cluding ADEM, classical AQP4-IgG+ NMOSD (n = 36), or
double-seronegative NMOSD (n = 7), mainly of Caucasian
descent (n = 50; Table 1), from neurologic departments of 23
tertiary referral centers in Germany (n = 13, all members of
the German Neuromyelitis Optica Study Group [NEMOS]),
France (n = 5, all members of the NOMADMUS cohort),
Austria (1), Italy (1), Switzerland (1), United Kingdom (1),
and United States of America (1) were retrospectively ana-
lyzed. The evaluated TCZ treatment period ranged from
December 2010 until November 2019. Regarding de-
mographic parameters (Table 1), the mean age at disease
manifestation was comparable for patients with MOGAD or
AQP4-IgG+ NMOSD (35.5 or 36.1 years, respectively; p =
0.89), as well as the age when TCZ was started (38.4 or 42.8
years, p = 0.35). Five patients were younger than 18 years at
disease manifestation, and 3 of them younger than 18 years at
initiation of TCZ. Of note, patients with AQP4-IgG+
Glossary
ADEM = acute disseminated encephalomyelitis; AQP4 = aquaporin-4; ARR = annualized relapse rate; AZA = azathioprine;
EDSS = Expanded Disability Status Scale;HDS = high-dose steroid; IL-6 = interleukin-6; IQR = interquartile range; IVIG = IV
immunoglobulin; LDS = low-dose steroid; MMF = mycophenolate mofetil; MOG = myelin oligodendrocyte glycoprotein;
MOGAD = myelin oligodendrocyte glycoprotein–IgG–associated disease; MTX = methotrexate; NMOSD = neuromyelitis
optica spectrum disorder; ON = optic neuritis; RTX = rituximab; SLE = systemic lupus erythematosus; TCZ = tocilizumab;
UTI = urinary tract infection.
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NMOSD were predominantly female, in contrast to patients
withMOGAD(91% vs 35% female, respectively). Patients with
AQP4-IgG+ NMOSD tended to have a longer history of dis-
ease (median 5.5 years) and were more severely affected at
TCZ start (median Expanded Disability Status Scale [EDSS]
score 6.25) than patients with MOGAD (median disease du-
ration 2.2 years, p = 0.13;median EDSS score 2.75, p< 0.01). In
the MOGAD group, 7 patients (50%) fulfilled the 2015 revised
international consensus diagnostic criteria for NMOSD.35 Be-
fore TCZ therapy, patients with MOGAD had had a median of
6 attacks (range 1–12 attacks) with 4.5 ON (median; range
1–10 ON) and 2.0 myelitis events (median; range 1–5 myelitis
events). In the NMOSD group, 5/7 double-seronegative
(71%) and 27/36 AQP4-IgG+ (75%) patients fulfilled the
2006 NMO diagnostic criteria,36 whereas all AQP4-IgG+ and
double-seronegative patients fulfilled the 2015 NMOSD di-
agnostic criteria.35 Of note, 47/57 (83%) patients were tested
for both antibodies, and none was double positive. Ten AQP4-
IgG+ patients were not tested for MOG-IgG. Before TCZ, all
patients had been treated with different immunotherapies fol-
lowing established recommendations, and, remarkably, all had
received rituximab (RTX) (Table 1; Figures 1 and 2 for sero-
positive patients). Within the last 24, 12, and 6 months before
TCZ switch, 53/57 (93%), 44/57 (77%), and 31/57 (54%) of
the patients were treated with RTX, respectively. B-cell counts,
collected briefly before the start of TCZ (median interval 0.9
months; interquartile range [IQR] 0.4–1.9 months), were
available for 33/57 (58%) patients (25/36 [69%] AQP4-IgG+
NMOSD, 6/14 [43%] MOGAD, and 2/7 [29%] double-
seronegative patients). Of these 33 patients, 28 (85%) patients
(21/25 [84%] AQP4-IgG+ NMOSD, 5/6 [83%] MOGAD,
and 2/2 [100%] double-seronegative patients) showed mark-
edly reduced or depleted B cells. During the total pre-TCZ
treatment phase (median duration of 2.9 years), patients had
6.0 attacks (median; range 1–30 attacks). Considering the last 2
years before TCZ start, 3.0 attacks (median; range 0–10 at-
tacks) were recorded (Table 1).
Methods
All clinical and paraclinical data were analyzed retrospectively by
chart review. Patients were continuously treated at the contrib-
uting centers, specialized in clinical neuroimmunology, with
regular assessment of clinical (attacks, EDSS score, and pain
levels) and paraclinical (MRI, AQP4- and MOG-IgG, and other
laboratory tests) data. AQP4-IgG and MOG-IgG antibodies
were exclusively measured by cell-based assays. The primary
outcome was the annualized relapse rate (ARR). An attack was
defined as definitely new neurologic symptom or clear acute
worsening of previous neurologic deficits with objective clinical
signs, lasting for at least 24 hours and attributed to an in-
flammatory CNS event, confirmed by the treating physician.
Safety aspects comprised infusion-related reactions, infections,
tumors, cardiovascular events, and standard laboratory tests.
AQP4-IgG titers, EDSS score, and chronic pain (occurrence and
intensity, classified asmild = 1,moderate = 2, or severe = 3)were
assessed at TCZ start and, if available, at last follow-up during
TCZ. MRI of the cervicothoracic spinal cord and the brain,
evaluated at TCZ onset and last available follow-up, was classi-
fied as nonactive or active, indicated by the presence of new T2
or contrast-enhancing lesions.
Statistical Analysis
In general, the ARR was calculated by dividing the number of
attacks within the last 2 years before TCZ switch or during
TCZ treatment time by 2. However, for 19 patients, who had
a TCZ pretreatment phase of <2 years (median 1.1 years), we
categorically divided the total number of attacks by 2, and for
13 patients with a follow-up period of <1 year (median 0.5
years) during TCZ treatment, we divided the number of at-
tacks by the concrete treatment duration and thus extrapo-
lated this measure to 1 year. To avoid possible overestimation
of the relapse-free proportion in the latter group, we excluded
those 13 patients with TCZ treatment durations of <12
months for subgroup analyses.
In the descriptive analysis, values are given as mean or median,
with the appropriate measures of dispersion (i.e., range, SD,
or IQR). In all cases, the assumption of normal distribution
could not be affirmed. Therefore, only nonparametrical tests
were used. To test for statistically significant differences be-
tween 2 related samples like ARR before TCZ switch and ARR
under TCZ therapy, theWilcoxon signed-rank test was used. In
case of paired categorical data with a dichotomous trait, the
exact binomial test was used. For count data–like relapses, we
also applied an unconditional Poisson regression. Statistical
results are presented as p values and 95% confidence intervals. p
Values <0.05 were considered to indicate statistically significant
results. Because of the exploratory nature of the study, no
adjustment for multiple comparisons was made. Version 3.6.3
of the R statistics package was used for statistical analysis.
Standard Protocol Approvals, Registrations,
and Patient Consents
Ethical approval was obtained from the Institutional Review
Board of the Heinrich Heine University Düsseldorf (#3419)
and from each participating center by their local institutional
review boards according to ICH/GCP. All patients provided
written informed consent.
Data Availability
Anonymized data not published within this article will be
made available by request from any qualified investigator.
Results
TCZ Reduced ARR
Forty-five of 57 (79%) patients switched to TCZ due to on-
going disease activity, 5/57 (9%) due side effects of prior
immunotherapies (including allergic reactions on RTX in 3
patients), and 6/57 (10%) because of concomitant disease
activity and adverse events. In 1 patient, the detection of
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Caucasian 13 (93) 30 (83) 7 (100) 50 (88)
African — 3 (8) — 3 (5)
Arabian 1 (7) 2 (6) — 3 (5)
Latin American — 1 (3) — 1 (2)
Sex, n: female/male (% female) 5/9 (35) 33/3 (91) 6/1 (85) 44/13 (77)
AQP4 serostatus, n: pos/neg (% positive) 0/14 (0) 36/36 (100) 0/7 (0) 36/21 (63)
MOG serostatus, n: pos/neg/NAa (% positive) 14/0/0 (100) 0/26/10 (0) 0/7/0 (0) 14/33/10 (25)
NMO based on 2006 criteria, n: yes/no (% yes) 4/10 (28) 27/9 (75) 5/2 (71) 36/21 (63)
NMO based on 2015 criteria, n: yes/no (% yes) 7/7 (50) 36/0 (100) 7/0 (100) 50/7 (87)
Age at disease manifestation, y: mean (SD) 35.5 (14.7) 36.1 (15.2) 42.7 (11.5) 36.8 (14.6)
Disease duration before TCZ, y: median (IQR) 2.2 (1.2–3.4) 5.5 (1.2–9.0) 2.4 (2.3–5.1) 2.9 (1.3–8.2)
Relapses under last immunotherapy, n: median (IQR) 1.5 (1.0–2.0) 1.0 (1.0–2.0) 3.0 (1.5–3) 1.0 (1.0–2.0)
Relapses during last 2 y before TCZ, n: median (IQR) 3.5 (2.2–5.0) 3.0 (2.0–5.0) 6.0 (2.5–6.0) 3.0 (2.0–5.0)
Age at TCZ start, y: mean (SD) 38.4 (15.0) 42.8 (14.6) 46.5 (10.8) 42.2 (14.3)
Number of TCZ infusions, n: mean (SD) 26.9 (21.7) 37.6 (31.1) 28.4 (21.9) 34.0 (28.2)
TCZ intervals, d: mean (SD) 30.8 (4.6) 32.1 (4.6) 30.4 (0.8) 31.6 (4.3)
TCZ treatment duration, mo: median (IQR) 16.3 (14.2–44.6) 27.9 (12.9–53.2) 30.4 (10.3–38.1) 23.8 (13.0–51.1)
Relapses before TCZ, n: median (IQR) 6.0 (4.2–8.0) 5.0 (3.0–10.2) 6.0 (5.5–8.5) 6.0 (3.0–9.0)
Relapses under TCZ, n: median (IQR) 0 (0–0) 0 (0–1.0) 1.0 (0–2.0) 0 (0–1.0)
EDSS score before TCZ: median (IQR) 2.75 (2.0–3.5) 6.25 (3.0–7.6) 5.0 (4.5–5.8) 4.5 (3.0–7.0)
EDSS score under TCZ: median (IQR) 2.0 (1.2–2.9) 4.25 (2.5–7.0) 5.0 (3.5–6.8) 3.5 (2.0–6.5)
Immunotherapies before TCZ, n (%):
Rituximab 14 (100) 36 (100) 7 (100) 57 (100)
Azathioprine 3 (21) 13 (36) 2 (29) 18 (32)
Mycophenolate mofetil 3 (21) 7 (19) 1 (14) 11 (19)
Low-dose steroid monotherapy 4 (29) 7 (19) 0 (0) 11 (19)
Methotrexate 1 (7) 7 (19) 3 (43) 11 (19)
Cyclophosphamide 2 (14) 8 (22) 1 (14) 11 (19)
IVIG 3 (21) 4 (11) 0 (0) 7 (12)
Interferon-beta 0 (0) 5 (14) 1 (14) 6 (11)
Mitoxantrone 0 (0) 5 (14) 0 (0) 5 (9)
Glatiramer acetate 0 (0) 2 (6) 1 (14) 3 (5)
Natalizumab 0 (0) 1 (3) 1 (14) 2 (4)
Long-term plasma exchange 1 (7) 1 (3) 0 (0) 2 (4)
Alemtuzumab 0 (0) 1 (3) 0 (0) 1 (2)
Fingolimod 0 (0) 1 (3) 0 (0) 1 (2)
Cyclosporin A 0 (0) 1 (3) 0 (0) 1 (2)
Continued
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neutralizing antibodies against RTX was the reason for
treatment switch. TCZ was administered IV (mean 34 infu-
sions, range 3–109) in 56 patients (98%) at a mean interval of
31.6 days (range 26.1–44.2 days) and with a median dose of
8.0 mg/kg body weight (range 6.0–12.0 mg/kg body weight;
Table 1) and subcutaneously in 1 patient (2%) with weekly
injections of 162 mg. The interval from last relapse to initia-
tion of TCZ was similar for all groups, i.e., 2.2 months (me-
dian, IQR 1.1–5.1 months) for patients with AQP4-IgG+
NMOSD, 3.2 months (1.5–4.8 months) for the MOGAD
subgroup, and 2.4 months (1.7–6.2 months) for double
seronegatives.
The median treatment duration was 23.8 months (IQR
13.0–51.1 months), with patients with AQP4-IgG+ NMOSD
showing the longest TCZ exposure (27.1 months), compared
with MOGAD (16.3 months) and double-seronegative (30.4
months) patients. In one-third of patients (20/57), TCZ was
given as an add-on treatment; in 2 of them due to comorbidities
(psoriasis cotreated with methotrexate [MTX]; chronic poly-
arthritis with oral low-dose steroids [LDSs]). Additional medi-
cations included LDS (n = 10), MTX (n = 4), mycophenolate
mofetil (MMF; n = 2), azathioprine (AZA; n = 1), IV immu-
noglobulins (IVIG; n = 1), RTX (n = 1), andmonthly high-dose
steroids (HDS; n = 1), administered for <6 months in 3 patients
and >6 months in 17 patients during TCZ treatment.
Initiation of TCZ was followed by a decrease of the
median ARR in patients with AQP4-IgG+ NMOSD from
1.5 to 0 (p < 0.001, 95% CI 0–0.2) compared with the last 2










Belimumab 1 (7) 0 (0) 0 (0) 1 (2)
Etanercept 0 (0) 1 (3) 0 (0) 1 (2)
Abbreviations: AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale;
MOG =myelin oligodendrocyte glycoprotein; MOGAD =MOG-IgG–associated disorder; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab.
a MOG-IgG ab not tested.
Figure 1 Disease Courses and Individual Maintenance Immune Therapies of Patients With MOGAD
First attacks are indicated as red diamonds and further attacks as blue diamonds. IVIG = IV immunoglobulin; IVMP = IV methylprednisolone; MOG = myelin
oligodendrocyte glycoprotein; MOGAD = MOG-IgG–associated disease.
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years before TCZ start. Of note, patients with MOGAD
showed a similar median ARR reduction from 1.75 to 0
(p = 0.0011, 95% CI 1.3–2.6). For patients with double-
seronegative NMOSD, median ARR reduction was less
prominent but still significant (from 3.0 to 0.2 [p < 0.032,
95% CI 0.3–2.8]). For the total cohort, the median ARR
decreased from 1.5 to 0 (p < 0.001, 95% CI 1.1–1.8;
Figure 3). Of note, ARR reductions were also detectable
when analysis was confined to those patients treated with
TCZ for at least 12 months, including MOGAD and
AQP4-IgG+ NMOSD, but not double-seronegative pa-
tients (Figure 3).
Regarding individual patients, 3/14 (21.4%) patients with
MOGAD (Figure 1) and 14/36 (39%) patients with AQP4-
IgG+ NMOSD (Figure 2) had at least 1 attack during TCZ
treatment, and 2/14 (14.3%) patients with MOGAD and 2/
36 (5.6%) patients with AQP4-IgG+ NMOSD showed 2 or
more attacks. Sixty percent of all patients were relapse free
(79% for MOGAD, 56% for AQP4-IgG+ NMOSD, and 43%
for double-seronegative NMOSD). When analyzing only
patients treated with TCZ for at least 12 months, 26/44
(59%) of all patients, 8/11 (73%) MOGAD, 16/28 (57%)
AQP4-IgG+, and 2/5 (40%) double-seronegative patients,
remained relapse free.
The median time to first relapse was 9 months (range 0.5–47
months) for the whole group, 9.4 months forMOGAD (range
9–15 months), 4.4 months for AQP4-IgG+ NMOSD (range
0.5–47 months), and 12.2 months for double-seronegative
NMOSD (range 2.6–18.9 months). An unconditional
Poisson regression analysis showed an average increase
in relapses by 16% per year under TCZ therapy, indicating
that a relapse is not expected until after 5 years under
TCZ in the total cohort (p < 0.03). Moreover, double-
seronegative patients had average 2.6 times the relapse
counts compared with patients with AQP4-IgG+ NMOSD
(p < 0.03), and in the MOGAD subgroup, relapses oc-
curred 8% less than in AQP4-IgG+ NMOSD, which was
not significant (p = 0.86).
When comparing patients treated with TCZ plus add-on
treatment (20/57) with those on TCZ monotherapy (37/
57), the ARR in the add-on group was higher in the 2 years
before TCZ initiation (median 2.0 [IQR 1–3] vs 1.5 [IQR
1–2.5]) as well as during TCZ treatment (0.2 [IQR 0–0.8] vs
0 [IQR 0-0]). In line, freedom from relapses was achieved in
40% of patients in the add-on group and in 78% in the
monotherapy group.
By comparing the 2 groups of patients who switched to TCZ
due to ongoing disease activity or side effects, the median
ARR in the first group was 2.0 (IQR 1.0–2.5) during the 2
years prior TCZ and was 0 (IQR 0–0.2) during TCZ treat-
ment, whereas the median ARRs were 1.0 (IQR 0.5–1.0) and
0 (IQR 0-0), respectively, for both intervals in the second
subgroup.
Relapsing vs Nonrelapsing Patients During
TCZ Treatment
When comparing patients who relapsed vs those who did not
relapse during TCZ treatment (across the different sub-
groups), relapsing patients with AQP4-IgG+ NMOSD were
younger at disease manifestation than nonrelapsing patients
(years, median, relapsing vs nonrelapsing, 31.4 vs 36.4, re-
spectively). At TCZ start, MOGAD and double-seronegative
patients who later relapsed were older than nonrelapsing
patients, whereas relapsing and nonrelapsing AQP4-IgG+
patients had comparable age (years, median, relapsing vs
nonrelapsing, AQP4-IgG+ 43.7 vs 43.6, MOGAD 48.5 vs
41.2, double seronegatives 50.7 vs 37.8, respectively). Re-
lapsing patients had a longer disease duration than non-
relapsing in the AQP4-IgG+ and MOGAD groups (years,
median, AQP4-IgG+ NMOSD 8.76 vs 2.93, MOGAD 3.33 vs
2.11, respectively). Sex had no effect on relapses in all sub-
groups. Under TCZ therapy, most of the myelitis and ON
attacks occurred in AQP4-IgG+ NMOSD and double-
seronegative patients (AQP4-IgG+ NMOSD: myelitis [14],
ON [4]; MOGAD: myelitis [2], ON + myelitis [1]; double
seronegatives: myelitis [4]).
TCZ Discontinuation
TCZ therapy was discontinued in 20/57 patients (35.1%;
15/36 [41.7%] AQP4-IgG+, 2/14 [14%] MOGAD, and 3/7
[42.9%] double-seronegative patients) after 14.5 treatment
months (median; range 2.9–53.9 treatment months). Of note,
45% (9/20) of them stopped TCZ for general reasons such as
pregnancy, plans for pregnancy, and patient’s preference (e.g.,
for oral medications), and 2 patients were lost to follow-up.
However, 6 of the 20 patients (2 AQP4-IgG+, 3 double se-
ronegative, and 1 MOGAD) presented ongoing MRI activity
or attacks, and 5/20 patients (all AQP4-IgG+) discontinued
due to suspected side effects such as ileus (n = 1), nephritis
and urticaria in the context of systemic lupus erythematosus
(SLE; n = 1), psoriasis exacerbation (n = 1), and upper re-
spiratory tract infections (n = 3). Two patients who stopped
TCZ restarted it after completion of pregnancy and ileus
treatment. Of the 11 patients with disease activity or sus-
pected side effects, 6 patients (55%) received TCZ as add-on
therapy, and 5 patients (45%) showed relapse activity, which
occurred 256 days (median, IQR 73–329 days) after TCZ
initiation, indicating that delayed onset of efficacy may have
contributed to early discontinuation.
Disability
The median EDSS score significantly decreased in both se-
ropositive groups, in MOGAD from 2.75 to 2.0 (p < 0.031)
and in AQP-IgG+ NMOSD from 6.25 to 4.25 (p < 0.003).
The median EDSS score remained stable on 5.0 in 7/7
double-seronegative patients (p < 0.77; Table 1; Figure 4).
When including patients with TCZ treatment duration
>12 months only, the EDSS score improvement was still
significant for AQP4-IgG+ NMOSD and the whole cohort
(Figure 4). The EDSS score worsened in only 5/57 (9%)
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Figure 2Disease Courses and IndividualMaintenance Immune Therapies of PatientsWith AQP4-IgG–Seropositive NMOSD
First attacks are indicated as red diamonds and further attacks as blue diamonds. AQP4 = aquaporin-4; IVIG = IV immunoglobulin; NMOSD = neuromyelitis
optica spectrum disorder; IVMP = IV methylprednisolone; PE = plasma exchange; SLE = systemic lupus erythematosus. (a) Twelve years before tocilizumab
(TCZ) initiation. (b) Twenty-four years before TCZ initiation. (c) Therapy of chronic polyarthritis 2 and a half years before TCZ initiation. (d) Fifteen years before
TCZ initiation. (e and f) Sixteen years before TCZ initiation. (g) Ten and a half years before TCZ initiation. (h) Twenty-two years before TCZ initiation. (i) Eleven
and a half years before TCZ initiation. (j) Psoriasis therapy; psoriasis flare-up finally remitted completely under rituximab; #loss to follow-up.
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patients of the entire cohort, i.e., none of patients with
MOGAD, 3/36 (8%) patients with AQP4-IgG+ NMOSD,
and 2/7 (29%) double-seronegative patients.
Pain
Initial disease-related chronic pain was reported in 28/51
patients (55%), with a median pain intensity of 2.0 (IQR 1–3;
data from 27 patients). Presence and intensity of pain were
not modulated during TCZ treatment, as 25/52 patients
(48%) still had ongoing chronic pain with a median intensity
of 2.0 (IQR 1–3; data available from 24 patients) at last
follow-up, regardless of the AQP4-IgG/MOG-IgG serostatus.
Antibody Titers
Regarding AQP4-IgG immunoreactivity, most patients (12/16)
showed decreased or stable titers after initiation of TCZ (Figure 5
for individual courses). Longitudinally assessed MOG-IgG anti-
body titers were available in only 2 of 14 patients and showed a
similar pattern as seen in AQP4-IgG+ NMOSD, i.e., a decrease
from 1:320 to 1:32 and from 1:1,280 to 1:10, respectively.
Magnetic Resonance Imaging
For brain MRI, the proportion of patients with active scans
(presence of new T2 or contrast-enhancing lesions) signifi-
cantly decreased from 43.5% at TCZ baseline (20/46 patients
with available longitudinal data at TCZ onset and follow-up)
to 15.2% (7/46 patients; p = 0.007) at last available scan,
within 31.6 months (mean; range 4.2–95.8 months). This
reduction was detectable for MOGAD (change from 7/13
[53.8%] to 1/13 patients [7.7%] with active scans; p = 0.031),
but not for AQP4-IgG+ (9/26 [34.6%] to 3/26 [11.5%]; p =
0.146) or seronegative (4/7 [57.1%] to 3/7 [42.9%]; p = 1)
subgroups.
For spinal cord MRI, the proportion of patients with active
scans decreased from 71.4% (25/35 patients) to 28.6% (10/
35; p = 0.00006) during TCZ (mean interval 40.5 months;
range 3.7–111.3). This effect was mainly driven by the AQP4-
IgG+ group with a decrease from 74.1% (20/27) to 25.9% (7/
27) of patients during TCZ (p = 0.0002). For double-
seronegative NMOSD and MOGAD, the proportion of pa-
tients with active scans was low and stable during TCZ.
Safety Data
Clinical Events
Infusion-related reactions occurred in 7/57 (12.3%) patients
and included headache, abdominal pain, vertigo, nausea, fa-
tigue, leg edema, rash, mild bruising, and bloating (Table 2).
Infections comprised recurrent urinary tract infections (UTI,
in 16% of patients), upper respiratory tract infections, com-
mon cold, bronchitis and pneumonia (in 16%), oral or lip
infections (in 7%; including herpes simplex virus, ulcers, and
candidiasis), erysipelas and skin lesions compatible with SLE
(in 5%), and (pyelo)nephritis (in 3.5%). In 19/57 (33%)
patients, 23 chronic underlying inflammatory diseases were
reported, including Hashimoto thyroiditis (N = 7), SLE (5),
psoriasis (4), Sjogren syndrome (2), and vitiligo, polyarthritis,
immune thrombocytopenic purpura, myasthenia gravis, and
Crohn disease (1 each). Exacerbation of SLE and psoriasis
Figure 3 ARR Before and During TCZ Treatment
Box-and-whisker plots showing the median, IQR, and range of the annualized relapse rate 2 years before and during TCZ treatment for the MOGAD (A), the
AQP4-IgG+ NMOSD (B) and the double seronegative (C) subgroups of patients, as well as for the total cohort (D). Each dot indicates 1 single patient. Hatched
bars represent those patients who had been treated with TCZ for at least 12 months. AQP4 = aquaporin-4; ARR = annualized relapse rate; IQR = interquartile
range; MOGAD = MOG-IgG–associated disease; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab.
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during TCZ occurred in 4 patients (2 from each) and led to
TCZ discontinuation in 2 of these 19 (11%) patients (both
AQP-IgG+ NMOSD). No new cancer occurred. One case of
type 1 focal nodular hyperplasia of the liver was diagnosed
during TCZ. Cardiovascular events occurred in 3 patients,
including a non-ST elevation myocardial infarction after the
initial infusion, a deep vein thrombosis, and a slight increase in
blood pressure. One death due to recurrent pneumonia oc-
curred 2 months after discontinuation of a 6-month TCZ
treatment period, but this was not regarded as treatment re-
lated by the treating physician, as the 58-year-old patient had a
history of severe AQP4-IgG+ NMOSD with concomitant
SLE and uterus carcinoma, including surgery and radiation.
TCZ-treated patients with additional immunotherapies suf-
fered more frequently from pneumonia compared with the
monotherapy group (18% vs 6%); other side effects like
reactivation of chronic latent infections (5% vs 6%) were
equally distributed in both groups.
Laboratory Changes
Neutropenia during TCZ treatment, with a maximum cell
count reduction of 61% below the lower reference level, oc-
curred in 10/57 (18%) patients, with 3 patients on a con-
comitant immunotherapy (MTX, RTX, and LDS; Table 2).
However, these 10 patients had no higher frequency of
common neutropenia-related conditions such as UTI, pneu-
monia, and other (unspecific) infections. Transient and mild
to moderate increases of liver enzymes and lipase (2- to 3-fold
above the upper reference level) were reported in 20/57
(35.1%) patients. In particular, alanine aminotransferase
was elevated at least once in 17/57 (29.8%) patients during
TCZ and increased from 28.2 U/L (mean; range 8–90 U/L;
at TCZ start) to 75.6 U/L (range 21–179 U/L; p < 0.001).
Mean total cholesterol levels increased slightly during
TCZ treatment from 195.3 mg/dL (n = 37/57; range
Figure 5 Longitudinal Aquaporin-4-IgG Titers Before and
During TCZ Treatment
Individual longitudinal courses of AQP4-IgG titers (assessed by cell-based
assays) for patients with AQP4-IgG–seropositive NMOSD (n = 16) are shown.
Most patients (12/16) showed decreased or stable titers on initiation of TCZ;
in 4/16 patients, the AQP4-IgG titer increased. AQP4 = aquaporin-4; NMOSD
= neuromyelitis optica spectrum disorder; TCZ = tocilizumab.
Figure 4 Level of Disability Measured as EDSS Score Before and During TCZ Treatment
Box-and-whisker plots showing the median, IQR, and range of the EDSS score 2 years before and during TCZ treatment for the MOGAD (A), the AQP4-IgG+
NMOSD (B) and the double seronegative (C) subgroups of patients, as well as for the total cohort (D). Each dot indicates 1 single patient. Hatched bars
represent those patients who had been treated with TCZ for at least 12 months. AQP4 = aquaporin-4; EDSS = Expanded Disability Status Scale; IQR =
interquartile range; MOGAD = MOG-IgG–associated disease; NMOSD = neuromyelitis optica spectrum disorder; TCZ = tocilizumab.
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59–311 mg/dL) to 203.8 mg/dL (n = 44/57; range
85–372 mg/dL; p = 0.5554), with no changes within the
subgroups as well. Similarly, low- and high-density lipo-
protein (LDL/HDL) cholesterol levels were stable during
TCZ (Table 2).
Discussion
Our study designed as a multicenter real-world approach
confirms and extends existing evidence, as it shows that
in MOG- or AQP4-IgG–mediated inflammatory demyelinating
syndromes, IL-6 blockade offers a therapeutic perspective,
even if patients were exposed to standard immunotherapies
before, including targeted B-cell depletion by RTX. Impor-
tantly, our data provide insights into therapeutic long-term
management of these diseases, with a follow-up far beyond
the observation periods in existing pivotal trials.
MOGAD in adults and NMOSD in general almost exclu-
sively follow a relapsing disease course,3,9 emphasizing the
relevance of attack prevention for disease prognosis.
Considering the long-term course, MOGAD was assumed
to have a less severe prognosis than NMOSD.37,38 How-
ever, recent studies indicate that retinal neuroaxonal
damage and visual impairment after ON are similar in both
diseases, suggesting that a higher attack rate in MOGAD,
compared with fewer, but more severe ON episodes in
AQP4-IgG+ NMOSD, results in comparable tissue
damage.39
Previous case series in NMOSD reported that IL-6R blockade
with TCZ confers beneficial effects for attack prevention in
retrospective and 1 prospective case series in NMOSD.20,24,40,41
Moreover, the recent TANGO trial showed that TCZ (n = 56
patients) better prevents NMOSD attacks than azathioprine
(n = 52 patients).42 Finally, 2 recent pivotal trials compared
satralizumab with placebo, either as a monotherapy (Sakur-
aStar)14 or as an add-on therapy (SakuraSky)13 and revealed
that satralizumab reduces the relapse rate, particularly in
AQP4-IgG+ NMOSD. However, follow-up in these trials
was rather short with a range of 60–90 weeks42 and a median
treatment duration in the double-blind period of 107.4










Infusion-related reactions, n (%) 1 (7%) 6 (17%) 0 (0%) 7 (12%)
Infections
Recurrent urinary tract infections 1 (7%) 7 (19%) 1 (14%) 9 (16%)
Viral upper respiratory tract infections/common cold/bronchitis/
pneumonia
2 (14%) 5 (14%) 2 (29%) 9 (16%)
Oral or lip infections 0 (0%) 4 (11%) 0 (0%) 4 (7%)
Erysipelas and skin lesions compatible with SLE 0 (0%) 3 (8%) 0 (0%) 3 (5%)
(Pyelo)nephritis 1 (/%) 1 (3%) 0 (0%) 2 (4%)
Reactivation of chronic latent infection, n (%) 0 (0%) 3 (8%) 0 (0%) 3 (5%)
Tumor, n (%) 0 (0%) 1a (3%) 0 (0%) 1a (2%)
Cardiovascular events, n (%) 0 (0%) 3 (8%) 1 (14%) 4 (7%)
Neutropenia, n (%) 2 (14%) 8 (22%) 0 (0%) 10 (17%)
Any liver enzyme changes, n (%) 2 (14%) 12 (33%) 6 (86%) 20 (35%)
Cholesterol before TCZ, mg/dL: mean (SD) 195.8 (42.2) 190.5 (65.0) 220.3 (66.8) 195.3 (58.5)
Cholesterol under TCZ, mg/dL: mean (SD) 199.6 (66.3) 199.9 (46.2) 235.2 (80.4) 203.8 (56.6)
LDL before TCZ, mg/dL: mean (SD) 126.9 (50.0) 114.0 (47.4) 140.7 (54.5) 121.0 (48.0)
LDL under TCZ, mg/dL: mean (SD) 129.8 (44.9) 119.2 (43.3) 166.3 (49.5) 126.4 (44.9)
HDL before TCZ, mg/dL: mean (SD) 60.6 (21.4) 59.4 (22.7) 66.3 (35.7) 60.5 (22.8)
HDL under TCZ, mg/dL: mean (SD) 70.7 (40.3) 69.8 (41.9) 57.8 (38.5) 68.9 (40.2)
Abbreviations: AQP4 = aquaporin-4; HDL = high-density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; MOG = myelin oligodendrocyte
glycoprotein; MOGAD = MOG-IgG–associated disorder; NMOSD = neuromyelitis optica spectrum disorder; SLE = systemic lupus erythematosus; TCZ =
tocilizumab.
SI conversion factors: to convert cholesterol, LDL and HDL to mmol/L, multiply values by 0.0259.
a FNH (focal nodular hyperplasia).
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and 92.3 weeks, respectively.13,14 Moreover, real-world
NMOSD patient cohorts on TCZ covered a limited num-
ber of patients (ranging from 3 to 19)20,24,40,41 and did not
investigate the effects of IL-6R blockade in MOGAD. Of
note, 12/36 patients with AQP4-IgG+ NMOSD from this
work were previously reported in 4 TCZ-specific
studies.21,22,25,26
In our study on 57 patients including 14 individuals with
MOGAD and 36 individuals with AQP4-IgG+ NMOSD,
we provide real-world data with a mean and maximum
treatment duration of nearly 3 and 9 years, respectively,
with 65% of patients receiving TCZ as monotherapy. The
mean ARR, as a primary outcome measure, significantly
decreased during TCZ treatment by 80% in the total cohort
and by 76% in the AQP4-IgG+ subgroup. Of note, our main
results—ARR reductions in MOGAD and AQP4-IgG+
NMOSD subgroups and the whole cohort—remained
stable when the analysis was restricted to patients receiving
TCZ for at least 12 months. Our findings confirm the re-
cent pivotal trials on the beneficial effects of IL-6 blockade
by satralizumab in NMOSD, particularly for AQP4-
IgG–seropositive patients. We also observed clinical sta-
bilization and reduced spinal cord MRI activity in AQP4-
IgG+ patients, along with decreased or stable AQP4-IgG
titers in most of them, whereas pain remained constant
during TCZ. The decrease of the EDSS score, spinal cord
MRI activity, and AQP4-IgG titers could at least in part be
explained by fact that baseline values were ascertained
during the acute phase and follow-up measures mainly
during remission phase while TCZ treatment. Beyond that,
the AQP4-IgG titer decrease/stabilization may also be an
indirect effect of the IL-6 blockade by TCZ, as IL-6 sig-
naling promotes the autoantibody production from plas-
mablasts in NMOSD.18 Our clinical and imaging findings
are in line with those in smaller retrospective case series and
the TANGO trial.22,23,41,42 The effect on pain remains
ambiguous, as it was reported in smaller case series,20,22 but
was not confirmed in our study or the satralizumab
SakuraSky trial.13
Regarding the patients with double-seronegative NMOSD,
we observed a significant ARR reduction, when considering
all 7 patients, independently of the treatment duration,
which was not reported in the pivotal trials for satralizumab
and could be explained by the heterogeneity of this less-
defined patient group, hampering direct comparisons.13,14
In line with the satralizumab studies, no effect on EDSS score,
pain, and, furthermore, on MRI activity, was detectable in
AQP4-IgG+ NMOSD in this study.
For MOGAD, treatment recommendations are scarce, and
approaches well established for AQP4-IgG+ NMOSD such
as CD20-mediated B-cell depletion have shown limited
efficacy in MOGAD.43-45 Another MOGAD treatment
study showed that under azathioprine therapy, 14 of 17
MOG-IgG+ patients (82%) had at least 1 attack, particu-
larly during the first 6 months and in patients without
concomitant steroid therapy.3 Reports on IVIG or MTX
treatment in MOGAD are so far rather anecdotal3,46;
however, recent data revealed the lowest ARR being asso-
ciated with an IVIG maintenance therapy (n = 10 patients),
compared with RTX, MMF, and AZA.45 Of note, recent
findings in a Chinese MOGAD cohort indicate that MMF
may prevent relapses, particularly with concomitant oral
prednisolone.47 Compared with untreated adult patients
with MOGAD, AZA, MMF, and RTX, but not MTX,
mitoxantrone, and cyclophosphamide, significantly re-
duced the risk of new relapses and the ARR in a cohort of
125 patients.48 So far, only 14 different MOGAD patients,
treated IV and/or subcutaneously with TCZ, were reported
in 7 small case reports/series23,26,29-33; 6 of these 14
patients were included in the present cohort.
Here, in our series of 14 patients with MOGAD, the ARR
decreased by 93%, the median EDSS score was reduced
from 2.75 to 2.0 over a mean TCZ treatment duration of
31 months, and an anti-inflammatory effect was obvious
also on brain MRI. Notably, the ARR reduction persisted
when considering only those patients who were treated for
more than 12 months. Again, the effect on EDSS score and
MRI activity was mainly driven by the fact of high disease
activity at baseline and remission phase at follow-up as-
sessment. Most patients with MOGAD (79% and 73%
for the patients treated for >12 months, respectively)
remained relapse free, and in 57% of them, TCZ was used
as monotherapy. The remaining 6 patients were cotreated
with LDS (n = 4), monthly HDS plus IVIG (n = 1), or
MTX (due to psoriasis, n = 1). No effects were found on
pain, which is a common symptom in MOGAD,49 and
spinal cord MRI activity. A single attack during TCZ
treatment occurred in 21% of patients with MOGAD, 2 or
4 attacks in 14% and 7% of patients, respectively. Our
findings are in line with those of a recent study, which
showed that TCZ therapy was associated with clinical and
radiographic relapse freedom, resolution of eye pain, and
ability to discontinue corticosteroids in a cohort of 10
patients with MOGAD over an average treatment duration
of 28.6 months.33 Overall, when considering disease ac-
tivity, including ARR, as well as suspected side effects
during TCZ therapy, we did not observe a clear advantage
of add-on treatments, supporting the use of TCZ as
monotherapy.
Considering safety, adverse events occurred within the
expected range based on the established use of TCZ in clinical
practice. Infusion-related reactions appeared in 12% of all
patients, and infections of the urinary or respiratory tract were
reported with similar frequency. Of note, (re)activation or
worsening of chronic latent inflammatory diseases was ob-
served in patients with already established SLE (n = 2) and
psoriasis (n = 2), indicating that these patients should be
particularly monitored. Laboratory changes included mild to
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moderate neutropenia in 18% and liver enzyme changes in
35% of patients. Total cholesterol, as well as HDL and LDL
cholesterol levels, did not change during TCZ treatment, as
expected.22
An obvious limitation of this study is the retrospective mul-
ticenter design resulting in heterogeneity of TCZ treatment
regimens andMRI protocols, as well as missing data, e.g., the
lack of MOG-IgG testing in 10/36 (28%) AQP4-IgG+ pa-
tients. However, the latter issue may not be a serious limi-
tation as co-occurrence of AQP4- and MOG-IgG at
significant titers is extremely rare.50 Another constraint is the
relatively small sample size, which is justifiable by the rarity
of NMOSD and MOGAD on a concomitant rare and
off-label treatment with TCZ. Nevertheless, we attempted
to enroll all of these seldom patients from 2 of the largest
cohorts in Europe, NEMOS in Germany and NOMADMUS
in France, and additional patients from other countries.
Moreover, because of the lack of a control cohort and the
timing of the switch to TCZ (i.e., during a phase of active
disease), we have to consider regression to the mean as
an important limitation of our study design, as mean dis-
ease activity could decrease spontaneously even without
treatment.
Despite these limitations, this largest real-world study
supports the long-term safety and therapeutic relevance of
the IL-6 pathway in RTX-refractory AQP4-IgG+ NMOSD
for up to 9 years. Moreover, our findings suggest a similar
role for MOGAD, pointing toward the need for random-
ized controlled trials to evaluate the efficacy of IL-6
blockade in patients with MOGAD. This study provides
Class III evidence that TCZ decreases the probability of
relapses in patients with refractory MOGAD and NMOSD.
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